<DOC>
	<DOCNO>NCT02741739</DOCNO>
	<brief_summary>Primary Objective : Determine blood concentration two formulation REGN1033 . Secondary Objective : Assess safety tolerability REGN1033 .</brief_summary>
	<brief_title>Study Blood Concentrations Two Formulations REGN1033 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key 1 . Healthy male female ( childbearing potential ) age 18 65 year 2 . Body weight 50.0 kg 95.0 kg 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent Key 1 . Donation loss approximately 400 mL blood within 8 week prior dose , plasma 14 day prior dose 2 . Hemoglobin within normal limit 3 . Positive drug alcohol screen test result screen visit 1 2 4 . Low elevate blood pressure and/or heart rate 3 minute rest seat position : 5 . Recent use ( within 3 month prior screen ) androgenic steroid 6 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives , whichever longer , investigational drug , prior screen visit 7 . Previous exposure biological therapeutic agent , except vaccine 8 . Known sensitivity tamoxifen , doxycycline , similar compound ( ie , tetracycline ) 9 . Pregnant breastfeed woman , woman childbearing potential 10 . Sexually active men unwilling practice adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug concentration</keyword>
	<keyword>REGN1033</keyword>
	<keyword>blood</keyword>
</DOC>